Clinical Trial Update: Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of Sym015 (anti-MET) in advanced solid tumors, including MET-amplified/non-small cell lung cancer, completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Met Gene Amplification Lung Cancer
• Met Gene Mutation
• Non-small Cell Lung Cancer

Drugs mentioned

• Sym015 (unknown)

Snippet

Sponsor: Symphogen A/S | Conditions: Oncology, MET Gene Amplification | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-06-22